Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold
Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.
Regenxbio's medicine for a rare disease hit a pause button from regulators because of concerning findings in patient spine scans. When a company's main medicine gets stopped, investors get worried, so the stock price fell sharply—and it's worth watching whether the company can fix the problem.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.